Novo Nordisk has announced the launch of its Wegovy weight‑loss pill in the United Arab Emirates. Elsa Ohlen of CNBC International reported the development.
Novo Nordisk, headquartered in Denmark, has built a reputation as a leader in diabetes and obesity medicines. Its portfolio includes several globally recognised products, and the company has a long‑standing presence in many regions.
Wegovy, already approved and widely used in the United States, is an injectable medication that targets the physiological mechanisms of appetite regulation. Making the drug available in the UAE means that local healthcare providers can now prescribe the treatment without relying on cross‑border supply chains.
Frequently asked questions
When was Wegovy launched in the UAE?Novo Nordisk has launched Wegovy in the UAE.
How does Wegovy work for weight loss?Wegovy is an injectable medication that targets appetite regulation mechanisms in the body to aid weight loss.
Why did Novo Nordisk choose the UAE for Wegovy?Novo Nordisk is expanding its distribution network to new geographies.
Is Wegovy available through UAE healthcare providers?Yes, local healthcare providers in the UAE can now prescribe Wegovy directly after its official launch.
What markets is Novo Nordisk targeting beyond the US?Novo Nordisk is expanding its market reach beyond the United States.
Source:CNBC
